Literature DB >> 11123488

Sequential improvement of anxiety, depression and anhedonia with sertraline treatment in patients with major depression.

P Boyer1, J P Tassin, B Falissart, S Troy.   

Abstract

OBJECTIVE: To establish the therapeutic effect profile of sertraline in major depression. It was hypothesized that the antidepressant effect of sertraline showed three phases: Phase 1 where improvements in anxiety are most pronounced; Phase 2 where the greatest improvements are in depressive symptoms; and Phase 3 where the symptoms of anhedonia show the most improvement. To test this hypothesis, an 8-week, open-label study was conducted.
METHODS: Patients with a major depressive episode (DSM-IV) and a score > or = 24 on the 17-item HAM-D were enrolled and treated with sertraline 50-150 mg/day. The three symptomatic clusters, anxiety, depression and hedonia, were defined a priori using the Inventory of Depressive Symptomatology-Clinician rated (IDS-C). Periods of interest were: Days 0-7 for anxiety, Days 7-21 for depression and Days 21-56 for anhedonia. Raters were blinded as to the constitution of the clusters and periods.
RESULTS: 140 patients were recruited. Improvement in the anxiety cluster of the IDS-C was greatest during Days 0-7, whereas over Days 7-21 most improvement was observed in the depression cluster and the greatest improvement in the hedonic cluster occurred during Days 21-56.
CONCLUSION: These preliminary results are consistent with the hypothesis that the therapeutic effects of sertraline occur in a sequential manner. The symptoms of anxiety improved first, followed by depression and then anhedonia.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11123488     DOI: 10.1046/j.1365-2710.2000.00302.x

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  7 in total

1.  Development of potent dopamine-norepinephrine uptake inhibitors (DNRIs) based on a (2S,4R,5R)-2-benzhydryl-5-((4-methoxybenzyl)amino)tetrahydro-2H-pyran-4-ol molecular template.

Authors:  Soumava Santra; Horrick Sharma; Seenuvasan Vedachalam; Tamara Antonio; Maarten Reith; Aloke Dutta
Journal:  Bioorg Med Chem       Date:  2014-12-25       Impact factor: 3.641

2.  Neural correlates of change in major depressive disorder anhedonia following open-label ketamine.

Authors:  Níall Lally; Allison C Nugent; David A Luckenbaugh; Mark J Niciu; Jonathan P Roiser; Carlos A Zarate
Journal:  J Psychopharmacol       Date:  2015-02-17       Impact factor: 4.153

3.  Pharmacological Treatments for Anhedonia.

Authors:  Matthew E Klein; Ariela Buxbaum Grice; Sahil Sheth; Megan Go; James W Murrough
Journal:  Curr Top Behav Neurosci       Date:  2022

4.  Enduring deficits in brain reward function after chronic social defeat in rats: susceptibility, resilience, and antidepressant response.

Authors:  Andre Der-Avakian; Michelle S Mazei-Robison; James P Kesby; Eric J Nestler; Athina Markou
Journal:  Biol Psychiatry       Date:  2014-01-31       Impact factor: 13.382

5.  SHAPS-C: the Snaith-Hamilton pleasure scale modified for clinician administration.

Authors:  Rezvan Ameli; David A Luckenbaugh; Neda F Gould; M Kathleen Holmes; Níall Lally; Elizabeth D Ballard; Carlos A Zarate
Journal:  PeerJ       Date:  2014-06-17       Impact factor: 2.984

6.  Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression.

Authors:  N Lally; A C Nugent; D A Luckenbaugh; R Ameli; J P Roiser; C A Zarate
Journal:  Transl Psychiatry       Date:  2014-10-14       Impact factor: 6.222

7.  Towards Modeling Anhedonia and Its Treatment in Zebrafish.

Authors:  Murilo S de Abreu; Fabiano Costa; Ana C V V Giacomini; Konstantin A Demin; Konstantin N Zabegalov; Gleb O Maslov; Yuriy M Kositsyn; Elena V Petersen; Tatiana Strekalova; Denis B Rosemberg; Allan V Kalueff
Journal:  Int J Neuropsychopharmacol       Date:  2022-04-19       Impact factor: 5.678

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.